结合临床参数及免疫组化标志物分析影响早期(Ⅰ期)子宫内膜癌复发的重要因素  

Combined with clinical parameters and immunohistochemical markers to analyze the important factors influencing the recurrence of early (stage Ⅰ) endometrial cancer

作　　者：贾明珠 胡琢瑛[1] JIA Mingzhu;HU Zhuoying(the First Affiliated Hospital of Chongqing Medical University,Chongqing 404000,China)

机构地区：[1]重庆医科大学附属第一医院,重庆404000

出　　处：《临床医学研究与实践》2020年第22期196-198,共3页Clinical Research and Practice

摘　　要：子宫内膜癌是妇科常见的恶性肿瘤之一,早期子宫内膜癌患者总体生存率较好,但是仍有部分早期患者经积极治疗后复发,复发成为患者术后死亡的主要原因之一。目前,临床医师根据患者的临床特征及术后病检制定术后管理方案,并且国内外有不少学者研究预测子宫内膜癌复发风险的危险因素,但其中部分因素存在争议并未达成共识,并且多数局限于临床参数,导致其临床应用有限。近年来随着分子生物学的发展,免疫组化标志物纳入影响早期子宫内膜患者复发的研究范围,有不少研究者认为结合免疫组化标志物及临床参数有助于提高预测复发的准确性。本文结合免疫组化标志物及临床参数分析影响早期子宫内膜癌复发的危险因素予以综述。Endometrial cancer is one of the common malignant tumors in gynecology.The overall survival rate of early endometrial cancer patients is better,but there are still some early patients who recurrence after positive treatment,which is one of the main causes of postoperative death.At present,the clinician for mulate the postoperative management plan according to the clinical characteristics and postoperative disease examination,and many scholars at home and abroad have studied the risk factors for predicting the risk of endometrial cancer recurrence,but some of the factor are still controversial and limited to the clinical parameters,resulting in limited clinical practice.In recent years,with the development of molecular biology,immunohistochemical markers have been included in the study of early endometrial recurrence.Many researchers believe that the combination of immunohistochemical markers and clinical parameters contribute to improve the accuracy of predicting recurrence.This article is to reviewed the risk factors affecting the recurrence of early stage endometrial cancer combining immunohistochemical markers and clinical parameters.

关 键 词：早期子宫内膜癌 免疫组化标志物 临床参数 复发 

分 类 号：R737.33[医药卫生—肿瘤]